Reference

c-MET Status

PD-L1 Status

Outcome (Pembrolizumab)

Mazieres et al. 2021 [23]

c-MET exon 14 skipping mutations

(N = 36/551)

PD-L1 > 1% in 66.8% of patients

ORR: 16%

mPFS: 3.4 mo.

mOS: 18 mo.

Sabari et al. 2018 [24]

c-MET exon 14 skipping mutations

(N = 147)

PD-L1 > 1% in 63% of patients

ORR: 17%

mPFS: 1.9 mo.

mOS: 18.2 mo.

Baba et al. 2019 [25] *

c-MET exon 14 skipping mutations

(N = 1, case report)

PD-L1: 95%

refractory to IOs, responsive to chemotherapy

Reis et al. 2018 [26] *

c-MET exon 14 skipping mutations

(N = 2, case report)

PD-L1: >50% in both patients

refractory to pembrolizumab